Daurisoline Modulates the TBK1-Dependent Type I Interferon Pathway to Boost Anti-tumor Immunity via Targeting of LRP1
1School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
2National Institute for Drug Clinical Trial, Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China.
3Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
4National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
5Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
6National Institutes for Food and Drug Control, Beijing 102629, China.
收起